Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.
- DOI
- 10.1001/jamanetworkopen.2022.55815
- Published
- 2023 Feb 1
- Container
- JAMA network open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1001/jamanetworkopen.2022.55815,
title = {Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.},
author = {Devgun JM and Zhang R and Brent J and Wax P and Burkhart K and Meyn A and Campleman S and Abston S and Aldy K and Toxicology Investigators Consortium FACT Study Group},
year = {2023},
journal = {JAMA network open},
doi = {10.1001/jamanetworkopen.2022.55815},
url = {https://doi.org/10.1001/jamanetworkopen.2022.55815}
}RIS
TY - JOUR TI - Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. AU - Devgun JM AU - Zhang R AU - Brent J AU - Wax P AU - Burkhart K AU - Meyn A AU - Campleman S AU - Abston S AU - Aldy K AU - Toxicology Investigators Consortium FACT Study Group PY - 2023 JO - JAMA network open DO - 10.1001/jamanetworkopen.2022.55815 UR - https://doi.org/10.1001/jamanetworkopen.2022.55815 ER -
APA
JM, D., R, Z., J, B., P, W., K, B., A, M., S, C., S, A., K, A., & Group, T. I. C. F. S. (2023). Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2022.55815
Source records
- pubmed · retrieved 2026-09-27T08:52:29.422Z
- europe-pmc · retrieved 2026-09-27T08:52:29.417Z